February 1, 2021

DEPARTMENT OF HEALTH
P. O. BOX 3378
HONOLULU, HI  96801-3378

In reply, please refer to:
File:

MEDICAL ADVISORY #19—CORONAVIRUS DISEASE 2019 (COVID-19):
COVID-19 VACCINATION CONTRAINDICATIONS, PRECAUTIONS, AND ADVERSE EVENT REPORTING

1. Vaccinating persons with a history of allergies

   Contraindications
   Persons with a history of an immediate allergic reaction (of any severity) to an mRNA COVID-19 vaccine or any of its components might be at greater risk for anaphylaxis. An immediate allergic reaction is defined as any hypersensitivity-related signs or symptoms such as urticaria, angioedema, respiratory distress (e.g., wheezing, stridor), or anaphylaxis that occur within four hours following administration.

   Precautions
   CDC considers a history of any immediate allergic reaction to any other vaccine or injectable therapy as a precaution but not a contraindication to vaccination for both the Pfizer-BioNTech and Moderna COVID-19 vaccines. Consider deferral of vaccination and/or referral to an allergist-immunologist.

Observation periods following vaccination with mRNA COVID-19 vaccines

**This message contains privileged communication between the Department of Health and clinicians and should not be shared with or forwarded to those not included among the original recipients.**
Persons with a history of an immediate allergic reaction of any severity to a vaccine or injectable therapy and persons with a history of anaphylaxis due to any cause should be observed for 30 minutes. All other persons should be observed for 15 minutes.

CDC guidance on COVID-19 vaccine contraindications and precautions is summarized in Appendix A. Additional clinical considerations for use of mRNA COVID-19 vaccines are available on the CDC website.

2. **Reporting of vaccine adverse events**

   - **VAERS**
     - Adverse events that occur in a recipient following mRNA COVID-19 vaccination should be reported in VAERS.
     - Vaccination providers are required by the Food and Drug Administration to report the following that occur after mRNA COVID-19 vaccination under Emergency Use Authorization:
       - Vaccine administration errors
       - Serious adverse events
       - Cases of Multisystem Inflammatory Syndrome
       - Cases of COVID-19 that result in hospitalization or death
     - Reporting is encouraged for any other clinically significant adverse event even if it is uncertain whether the vaccine caused the event. Information on how to submit a report to VAERS is available at [https://vaers.hhs.gov](https://vaers.hhs.gov) or by calling 1-800-822-7967.

   - **V-safe**
     - Healthcare providers are encouraged to support their patients in participating in V-safe to report possible side effects following vaccination.
     - V-safe is CDC’s new, voluntary smartphone-based tool. This tool uses text messaging and web surveys to perform health check-ins after patients receive COVID-19 vaccination. Reports to v-safe indicating a medically significant health impact are followed up by the CDC/v-safe call center.

3. **Considerations for clinical judgement**

   Because patients with a history of severe or immediate allergic reaction to any injectable therapy may be at higher risk of adverse reactions, it is preferable for these individuals to be vaccinated under direct observation and in a setting where advanced medical care is readily available. These patients are not being vaccinated at Department of Health (DOH)-run vaccination Points of Dispensing (POD). Those with a history of other allergies can be vaccinated at DOH-run PODs with a 30 min observation period.

**This message contains privileged communication between the Department of Health and clinicians and should not be shared with or forwarded to those not included among the original recipients.**
As vaccine becomes more widely available individual clinical judgement will play its usual role and vaccine providers may choose to vaccinate some individuals not vaccinated in mass-vaccine settings, with appropriate safeguards, counseling, and availability of advanced medical care.

4. **For more information and updates**
   
   - [Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently Authorized in the United States | CDC](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/clinical-considerations.html)

Healthcare personnel or health departments in the United States can request a consultation from the [Clinical Immunization Safety Assessment COVIDvax](https://www.cdc.gov/vaccines/covidvax) project for a complex COVID-19 vaccine safety question about an individual patient residing in the United States not readily addressed by CDC guidance.

**Information and guidance on COVID-19 continues to evolve.** To ensure you are accessing the latest information, please visit [HDOH’s COVID-19 webpage](https://hawaii.gov/hdoh/covid-19) or [CDC’s COVID-19 website](https://www.cdc.gov/coronavirus/2019-ncov/index.html).

If you have any questions or need to report a patient with suspected/confirmed COVID-19, please contact us at one of the numbers below.

- Oahu (Disease Reporting Line)………………. (808) 586-4586
- Maui District Health Office………………………….. (808) 984-8213
- Kauai District Health Office…………………….. (808) 241-3563
- Big Island District Health Office (Hilo)……………. (808) 933-0912
- Big Island District Health Office (Kona)……………. (808) 322-4877
- After hours on Oahu……………………………. (808) 600-3625
- After hours on neighbor islands…………………..(800) 360-2575 (toll free)

We appreciate your partnership to prevent the spread of COVID-19 in our communities.

Sincerely,

Sarah Kemble, MD
Acting State Epidemiologist

**REFERENCES**


**This message contains privileged communication between the Department of Health and clinicians and should not be shared with or forwarded to those not included among the original recipients.**

**This message contains privileged communication between the Department of Health and clinicians and should not be shared with or forwarded to those not included among the original recipients.**
### Appendix A: Triage of persons presenting for mRNA COVID-19 vaccination

**MAY PROCEED WITH VACCINATION**

<table>
<thead>
<tr>
<th>CONDITIONS</th>
<th>ACTIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Immunocompromising conditions</td>
<td>• Additional information provided*&lt;br&gt;• 15 minute observation period</td>
</tr>
<tr>
<td>• Pregnancy</td>
<td></td>
</tr>
<tr>
<td>• Lactation</td>
<td></td>
</tr>
</tbody>
</table>

**PRECAUTION TO VACCINATION**

<table>
<thead>
<tr>
<th>CONDITIONS</th>
<th>ACTIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Moderate/severe acute illness</td>
<td>• Risk assessment&lt;br&gt;• Potential deferral of vaccination&lt;br&gt;• 15-minute observation period if vaccinated</td>
</tr>
</tbody>
</table>

**CONTRAINDICATION TO VACCINATION**

<table>
<thead>
<tr>
<th>CONDITIONS</th>
<th>ACTIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>• None</td>
<td>• N/A</td>
</tr>
</tbody>
</table>

**ALLERGIES**

- History of allergies that are unrelated to components of an mRNA COVID-19 vaccine†, other vaccines, injectable therapies, or polysorbate, such as:
  - Allergy to oral medications (including the oral equivalent of an injectable medication)<br>• History of food, pet, insect, venom, environmental, latex, etc., allergies<br>• Family history of allergies

**ALLERGIES**

- History of any immediate allergic reaction‡ to vaccines or injectable therapies (except those related to component of mRNA COVID-19 vaccines† or polysorbate, as these are contraindicated)

**ACTIONS:**

- Risk assessment<br>• Consider deferral of vaccination and/or referral to allergist-immunologist<br>• 30-minute observation period if vaccinated

**ALLERGIES**

- Severe allergic reaction (e.g., anaphylaxis) after a previous dose of an mRNA COVID-19 vaccine or any of its components<br>• Immediate allergic reaction† of any severity to a previous dose of an mRNA COVID-19 vaccine or any of its components (including polyethylene glycol)^#<br>• Immediate allergic reaction of any severity to polysorbate^#

**ACTIONS:**

- Do not vaccinate#<br>• Consider referral to allergist-immunologist

---

* See Special Populations section for information on patient counseling in these groups

† Refers only to mRNA COVID-19 vaccines currently authorized in the United States (i.e., Pfizer-BioNTech, Moderna COVID-19 vaccines)

‡ Immediate allergic reaction to a vaccine or medication is defined as any hypersensitivity-related signs or symptoms consistent with urticaria, angioedema, respiratory distress (e.g., wheezing, stridor), or anaphylaxis that occur within four hours following administration.

^ See Appendix B for a list of ingredients. Note: Polyethylene glycol (PEG), an ingredient in both mRNA COVID-19 vaccines, is structurally related to polysorbate and cross-reactive hypersensitivity between these compounds may occur. Information on ingredients of a vaccine or medication (including PEG, a PEG derivative, or polysorbates) can be found in the package insert.

# These persons should not receive mRNA COVID-19 vaccination at this time unless they have been evaluated by an allergist-immunologist and it is determined that the person can safely receive the vaccine (e.g., under observation, in a setting with advanced medical care available)
**Vaccine Adverse Event Reporting System (VAERS)**

The Vaccine Adverse Event Reporting System (VAERS), is a national program managed by the U.S. Centers for Disease Control and Prevention (CDC) and the U.S. Food and Drug Administration (FDA) to monitor the safety of all vaccines licensed in the United States. VAERS collects and reviews reports of adverse events that occur after vaccination. An “adverse event” is any health problem or “side effect” that happens after a vaccination. VAERS cannot determine if a vaccine caused an adverse event, but can determine if further investigation is needed.

**VAERS provides valuable information**

VAERS is an early-warning system that detects problems possibly related to vaccines. The system relies on reports from healthcare providers*, vaccine manufacturers, and the general public. Reporting gives CDC and FDA important information to identify health concerns and ensure vaccines are safe in order to protect the public’s health.

**VAERS staff evaluate reports of adverse events**

VAERS defines a “serious adverse event” as life-threatening illness, hospitalization, prolongation of an existing hospitalization, permanent disability or death. Once adverse events are identified using VAERS, they may be monitored in other immunization safety systems to confirm if a particular adverse event is related to a vaccination and identify any specific risk factors.

**Anyone can report to VAERS**

Anyone can submit a report to VAERS, including patients, family members, healthcare providers, vaccine manufacturers and the general public. CDC and FDA encourage anyone who experiences an adverse event after receiving a vaccine to report to VAERS.

**How to report to VAERS**

You can report to VAERS online at [https://vaers.hhs.gov/index](https://vaers.hhs.gov/index).

For further assistance reporting to VAERS, visit [https://vaers.hhs.gov/index](https://vaers.hhs.gov/index) or contact VAERS directly at info@VAERS.org or 1-800-822-7967.

**VAERS data are available to the public**

VAERS data can be downloaded at [https://vaers.hhs.gov/data/index](https://vaers.hhs.gov/data/index) or searched at [http://wonder.cdc.gov/vaers.html](http://wonder.cdc.gov/vaers.html). Privacy is protected and personal identifying information (such as name, date of birth and address) is removed from the public data.

*Healthcare providers are encouraged to report all clinically significant adverse events after vaccination to VAERS even if it is uncertain whether the vaccine caused the event. They are also required to report to VAERS adverse events found in the Reportable Events Table (RET) at [https://vaers.hhs.gov/resources/VAERS_Table_of_Reportable_Events_Following_Vaccination.pdf](https://vaers.hhs.gov/resources/VAERS_Table_of_Reportable_Events_Following_Vaccination.pdf)
What is v-safe?

**V-safe** is a smartphone-based tool that uses text messaging and web surveys to provide personalized health check-ins after you receive a COVID-19 vaccination. Through **v-safe**, you can quickly tell CDC if you have any side effects after getting the COVID-19 vaccine. Depending on your answers, someone from CDC may call to check on you. And **v-safe** will remind you to get your second COVID-19 vaccine dose if you need one.

Your participation in CDC’s **v-safe** makes a difference—it helps keep COVID-19 vaccines safe.

How can I participate?

Once you get a COVID-19 vaccine, you can enroll in **v-safe** using your smartphone. Participation is voluntary and you can opt out at any time. You will receive text messages from **v-safe** around 2pm local time. To opt out, simply text “STOP” when **v-safe** sends you a text message. You can also start **v-safe** again by texting “START.”

How long do v-safe check-ins last?

During the first week after you get your vaccine, **v-safe** will send you a text message each day to ask how you are doing. Then you will get check-in messages once a week for up to 5 weeks. The questions **v-safe** asks should take less than 5 minutes to answer. If you need a second dose of vaccine, **v-safe** will provide a new 6-week check-in process so you can share your second-dose vaccine experience as well. You’ll also receive check-ins 3, 6, and 12 months after your final dose of vaccine.

Is my health information safe?

Yes. Your personal information in **v-safe** is protected so that it stays confidential and private.*

*To the extent **v-safe** uses existing information systems managed by CDC, FDA, and other federal agencies, the systems employ strict security measures appropriate for the data’s level of sensitivity. These measures comply, where applicable, with the following federal laws, including the Privacy Act of 1974; standards enacted that are consistent with the Health Insurance Portability and Accountability Act of 1996 (HIPAA); the Federal Information Security Management Act, and the Freedom of Information Act.
How to register and use v-safe

You will need your smartphone and information about the COVID-19 vaccine you received. This information can be found on your vaccination record card; if you cannot find your card, please contact your healthcare provider.

Register

1. Go to the v-safe website using one of the two options below:

   Use your smartphone's browser to go to vsafe.cdc.gov

   OR

   Aim your smartphone's camera at this code

2. Read the instructions. Click Get Started.
3. Enter your name, mobile number, and other requested information. Click Register.
4. You will receive a text message with a verification code on your smartphone. Enter the code in v-safe and click Verify.
5. At the top of the screen, click Enter your COVID-19 vaccine information.
6. Select which COVID-19 vaccine you received (found on your vaccination record card; if you cannot find your card, please contact your healthcare provider). Then enter the date you were vaccinated. Click Next.
7. Review your vaccine information. If correct, click Submit. If not, click Go Back.
8. Congrats! You're all set! If you complete your registration before 2pm local time, v-safe will start your initial health check-in around 2pm that day. If you register after 2pm, v-safe will start your initial health check-in immediately after you register—just follow the instructions.
   
   You will receive a reminder text message from v-safe when it’s time for the next check-in—around 2pm local time. Just click the link in the text message to start the check-in.

Complete a v-safe health check-in

1. When you receive a v-safe check-in text message on your smartphone, click the link when ready.
2. Follow the instructions to complete the check-in.

Troubleshooting

How can I come back and finish a check-in later if I'm interrupted?

- Click the link in the text message reminder to restart and complete your check-in.

How do I update my vaccine information after my second COVID-19 vaccine dose?

- v-safe will automatically ask you to update your second dose information. Just follow the instructions.

Need help with v-safe?
Call 800-CDC-INFO (800-232-4636)
TTY 888-232-6348
Open 24 hours, 7 days a week
Visit www.cdc.gov/vsafe